This content was archived on June 24, 2013.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Transdermal fentanyl (Duragesic): abuse in adolescents

Duragesic (fentanyl transdermal system) has been marketed in Canada since 1992 and is indicated for the management of chronic pain in patients requiring continuous opioid analgesia for pain that is not optimally managed with weak or short-acting opioids. Opioid-naive patients may be at risk of overdose with the use of opioid drugs, including fentanyl.

From Jan. 1, 1998, to Jan. 31, 2005, Health Canada received 4 reports of abuse of Duragesic patches by adolescent boys aged 14–17 years. Three of the boys died, and 1 had not recovered at the time of reporting. The patches were found either in home medicine cabinets or were prescribed to a parent. In 3 cases the use of marijuana was reported.

From 28% to 84% of the active ingredient may be recovered from a fentanyl transdermal system even after 3 days of therapeutic use, which is more than sufficient drug for potential abuse. The fentanyl from the patch can be abused by ingestion, intravenous injection, volatilization and inhalation, or application of multiple patches, and such abuse may result in death. Potential for overdose also exists when heating pads are applied to the skin to raise skin temperature and increase the rate of fentanyl absorption from the patch. In addition, low concentrations of fentanyl are sufficient to induce respiratory depression.

Abuse of fentanyl patches depends on access to improperly discarded or secured patches. The Canadian product monograph provides recommendations for the safe disposal of Duragesic patches. Specific information for the patient details the risks of Duragesic and how to apply, remove and dispose of the transdermal patches. Safe and secure dispensing, storage and disposal measures must be reinforced for patients, pharmacists and physicians.

References
Black cohosh: international reports of liver toxicity

Black cohosh (Cimicifuga racemosa) is an herbal medicine used mainly to alleviate menopausal symptoms. Adverse reactions (ARs) to black cohosh include gastrointestinal irritation, headache, dizziness and vomiting.¹ Recently, there have been international case reports of liver dysfunction suspected to be associated with its use.

As of March 31, 2005, the United Kingdom’s Medicines and Healthcare products Regulatory Agency received 20 reports of liver reactions suspected of being associated with the use of black cohosh.² The cases ranged in severity from abnormal liver function test results to various forms of hepatitis. At the time of reporting, most of the patients had recovered or were recovering. In addition, a case of hepatic failure associated with the use of black cohosh was recently published.³ From Jan. 1, 1998, to Feb. 28, 2005, Health Canada received 7 reports of ARs suspected of being associated with ingestion of black cohosh. There were no reports of liver dysfunction. All of the cases involved women, aged 33 to 55 years. Some of the ARs reported included dizziness, rash, pruritus, edema, increased pulse rate, bradycardia, atrial fibrillation, changes in serum thyroid levels, vaginal bleeding and convulsions. Causality could not be assigned specifically to black cohosh because most of the reports contained insufficient clinical information and lacked details on the use of concomitant medications.

Since January 2004, all natural health products, including those containing black cohosh, are covered under the new Natural Health Products Regulations. Health Canada encourages health care providers and the public to report any suspected ARs related to natural health products to Health Canada.

Chad Sheehy BS, ND; Mano Murty MD, CCFP, FCFP; Karen Pilon, RN, Health Canada

References

Rosiglitazone (Avandia): decreased high-density lipoprotein cholesterol levels

Rosiglitazone (Avandia) is a member of the thiazolidinedione family of oral hypoglycemic agents used to improve glycemic control by increasing insulin sensitivity in muscle and adipose tissue and inhibiting hepatic gluconeogenesis.¹ It has been marketed in Canada since March 2000.

Clinical trials using rosiglitazone as monotherapy detected increases in levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) and decreases in levels of free fatty acids.¹ Decreased HDL-C levels were not seen in over 1400 patients treated with rosiglitazone in clinical trials.² It is noteworthy that fibrates are used to improve HDL-C and triglyceride levels but generally have a beneficial effect on the lipid values resolved 2 months after stopping the rosiglitazone therapy.³ In all 3 cases, the HDL-C level at this time was 1.06 mmol/L. Approximately 3 months later the HDL-C level had decreased to 0.27 mmol/L, the triglyceride level had increased from 1.4 to 3.4 (target level in high-risk patients < 1.5) mmol/L, and the total cholesterol:HDL-C ratio increased from 4 to 15.4 (target level in high-risk patients < 4). Following discontinuation of the rosiglitazone therapy after 7 months of use, there was an increase in the HDL-C level to 0.8 mmol/L and a reduction in the total cholesterol: HDL-C ratio to 5.3. The abnormal lipid values resolved 2 months after stopping the rosiglitazone therapy. The reporter did not state whether treatment with fenofibrate was continued. Subsequently, the patient developed symptoms of angina and underwent angioplasty.

The medical literature describes 3 cases of profound decreases in HDL-C and apolipoprotein A-I concentrations during treatment with rosiglitazone.² Triglyceride levels also increased during treatment. In all 3 cases, the HDL-C level increased after withdrawal of the rosiglitazone. Two patients were taking a fibrate but did not have a decreased HDL-C level until rosiglitazone was introduced.

Given the findings of the 3 cases from the medical literature and the Canadian case, in patients prescribed rosiglitazone, it would be advisable to measure baseline HDL-C and triglyceride levels and check them again shortly after the start of therapy.

Debra Willcox BSP, Health Canada

References
Ibuprofen: Stevens–Johnson syndrome

Stevens–Johnson syndrome (SJS) is a severe blistering rash affecting both skin and mucous membranes. The majority of cases have been attributed to drug exposures. The reaction begins with burning and painful lesions on the face and upper torso and extends to the rest of the body. Blistering and epidermal detachment may occur. Patients may present with fever, malaise, myalgia and ocular manifestations. Mortality has been estimated at 5% of cases.

From Jan. 1, 1973, to Feb. 21, 2005, Health Canada received 4 reports of SJS suspected of being associated with ibuprofen. At the time of reporting, 3 patients had not recovered, and the outcome was unknown for 1 patient. The reports involved patients aged 13 to 34 years and were all received after April 2001. The dosages ranged from 200 mg to 1200 mg daily. The onset of reactions varied from the day of administration to approximately 15 days after starting ibuprofen. In one report, carbamazepine was indicated as a suspect drug along with ibuprofen. Ibuprofen has been available over the counter since August 1989. SJS is listed in the product monographs for ibuprofen products. Although cases of SJS remain rare, patients taking ibuprofen should be warned to discontinue use and seek medical attention should any rash, fever without an alternative explanation or mucosal symptoms develop.

Sally Pepper, BScPhm; Heather Morrison, BSc (Biology), MLIS, Health Canada

References
5. Advil (ibuprofen) [product monograph]. Mississauga (ON): Whitbread Robbins Inc.; 2004

New Regional Adverse Reaction Centres

The Canadian Adverse Drug Reaction Monitoring Program (CADRMP), a program of Health Canada’s Marketed Health Products Directorate, is pleased to announce the establishment of two new Regional Adverse Reaction (AR) Centres, one in Alberta and one in Manitoba. They have joined the existing Regional AR Centres — currently located in British Columbia, Saskatchewan, Ontario, Quebec and Atlantic Canada — as the regional points-of-contact for the CADRMP. As of April 2005, health care professionals and consumers in Alberta and Manitoba can report ARs to these new centres using the program’s toll free numbers:

Alberta Regional Adverse Reaction Centre
Rm. 114, 510 Lagimodière Blvd.
Winnipeg MB R2J 3Y1
Tel: 866 234-2345
Fax: 866 678-6789

Manitoba Regional Adverse Reaction Centre
c/o Ste. 730, 9700 Jasper Ave.
Edmonton AB T5J 4C3

Case presentation

Recent Canadian cases are selected based on their seriousness, frequency of occurrence or the fact that the reactions are unexpected. Case presentations are considered suspicions and are presented to stimulate reporting of similar suspected adverse reactions.

Mefloquine: suspected association with QT prolongation

A 20-year-old man with no significant medical history and taking no other medications experienced prolongation of the QT interval after receiving Apo-Mefloquine, 250 mg once weekly for 4 weeks, for malaria prophylaxis. Two days after taking the fourth dose of mefloquine, he presented with dizziness, headache, nausea and tingling in the arms followed by a decreased level of consciousness. He became hypotensive and required hospital admission. An electrocardiogram (ECG) showed prolonged QT intervals (432 ms, 402 ms and 484 ms). The echocardiogram yielded normal findings. Information such as electrolyte levels and corrected QT intervals were not specified by the reporter. The mefloquine therapy was stopped, and the patient received an epinephrine infusion for a short period. An ECG repeated 8 days later showed a QT interval of 380 ms. Cases of QT prolongation during treatment with mefloquine have been described in the literature.

References
Adverse reactions (ARs) to health products are considered to be suspicions, as a definite causal association often cannot be determined. Spontaneous reports of ARs cannot be used to estimate the incidence of ARs because ARs remain underreported and patient exposure is unknown.

<table>
<thead>
<tr>
<th>Date</th>
<th>Product</th>
<th>Subject and type</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 13</td>
<td>New Choice Pregnancy Test</td>
<td>Advisory not to use New Choice Pregnancy Test — consumer information</td>
</tr>
<tr>
<td>May 12</td>
<td>Diane-35</td>
<td>Diane-35: new warning — consumer information</td>
</tr>
<tr>
<td>May 12</td>
<td>Master’s Miracle &amp; Miracle II</td>
<td>Warning not to use Master’s Miracle Fortified Mineral Neutralizer or Miracle II Miracle Neutralizer — consumer information</td>
</tr>
<tr>
<td>May 12, Apr 22, 15 &amp; 14</td>
<td>Avandamet, Avandia, Coreg, Paxil, Paxil CR, Releif and ratio-Paroxetine</td>
<td>Safety Information and update — consumer information update — consumer information — GlaxoSmithKline Inc. health professional communication — ratiopharm Inc. health professional communication</td>
</tr>
<tr>
<td>May 6</td>
<td>Xigris</td>
<td>Xigris: safety information — Eli Lilly Canada Inc. — health professional communication</td>
</tr>
<tr>
<td>Apr 29</td>
<td>Pms-Sodium Polysterene Sulfonate</td>
<td>Warning not to consume a certain lot of pms-Sodium Polysterene Sulfonate for Suspension — consumer information</td>
</tr>
<tr>
<td>Apr 27</td>
<td>Elidel and Protopic</td>
<td>Elidel cream and Protopic ointment: safety information — consumer information</td>
</tr>
<tr>
<td>Apr 27</td>
<td>Trileptal</td>
<td>Trileptal: life-threatening dermatological reactions and multi-organ hypersensitivity — Novartis Pharmaceuticals Canada Inc. — health professional communication</td>
</tr>
<tr>
<td>Apr 26</td>
<td>Magnetic resonance imaging</td>
<td>Transdermal drug patches: thermal burns during magnetic resonance imaging (MRI) procedures — notice to hospitals</td>
</tr>
<tr>
<td>Apr 21</td>
<td>Bextra</td>
<td>Bextra: serious adverse drug reactions — Pfizer Canada Inc. — health professional communication</td>
</tr>
<tr>
<td>Apr 19</td>
<td>Blood glucose meters</td>
<td>LifeScan models of blood glucose monitoring systems: safety information — LifeScan — consumer information</td>
</tr>
<tr>
<td>Apr 18</td>
<td>Reminyl</td>
<td>Reminyl in mild cognitive impairment: investigational studies — Janssen-Ortho Inc. — health professional communication</td>
</tr>
<tr>
<td>Apr 7</td>
<td>Bextra and Celebrex</td>
<td>Sales suspension of Bextra and new restrictions on Celebrex — consumer information</td>
</tr>
<tr>
<td>Mar 31</td>
<td>Ergolift Patient Lifts</td>
<td>BHM Ergolifts: reliability of the actuator — notice to hospitals</td>
</tr>
<tr>
<td>Mar 24 &amp; 23</td>
<td>Icodextrin</td>
<td>Icodextrin-containing peritoneal dialysis solutions: falsely elevated blood glucose monitor readings — consumer information and notice to hospitals</td>
</tr>
<tr>
<td>Mar 14</td>
<td>WT-5200 Warming Units</td>
<td>Electrically heated blankets: fire and burn risks — consumer information</td>
</tr>
<tr>
<td>Mar 12</td>
<td>Cough Syrup DM</td>
<td>Advisory not to use Cough Syrup DM DIN 02015781, lot numbers starting with 2J29 and 3J29 — consumer information</td>
</tr>
<tr>
<td>Mar 8 &amp; 3</td>
<td>Crestor</td>
<td>Crestor: muscle-related adverse events — AstraZeneca Canada Inc. consumer information and health professional communication — consumer information</td>
</tr>
<tr>
<td>Mar 3</td>
<td>Ayurvedic products</td>
<td>Ayurvedic medicinal products: high levels of heavy metals — consumer information</td>
</tr>
<tr>
<td>Mar 3</td>
<td>Aristolochic acid</td>
<td>Reminder not to use products containing aristolochic acid — consumer information</td>
</tr>
<tr>
<td>Feb</td>
<td>Marquis ICD and CRT-D</td>
<td>Medtronic implantable cardiac defibrillators: safety information — Medtronic of Canada Ltd. — health professional communication</td>
</tr>
</tbody>
</table>

To receive the Newsletter and health product Advisories free by email, join Health Canada’s Health_Prod_Info mailing list. Go to www.hc-sc.gc.ca/tpd-dpt/subscribe_e.html.